- Home
- AGMH vs CYCN Comparison
AGMH vs CYCN Comparison
Compare AGMH & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMH | CYCN |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGMH | CYCN |
|---|---|---|
| Price | $2.36 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.3K | ★ 46.2K |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 16.43 | N/A |
| Revenue | ★ $48,526,743.00 | $2,855,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.12 | ★ N/A |
| Revenue Growth | 18.80 | ★ 1371.65 |
| 52 Week Low | $1.09 | $1.28 |
| 52 Week High | $89.00 | $6.25 |
Technical Indicators
Market Signals| Indicator | AGMH | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 26.49 | 41.04 |
| Support Level | $2.75 | $1.43 |
| Resistance Level | $2.97 | $1.64 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 5.97 | 17.84 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.